Diversion Control Division, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

October

Bulk Manufacturers of Marihuana; Correction (October 11, 2019)

Cambridge Isotope Laboratories, Inc. (October 7, 2019)

Bulk Manufacturer of Controlled Substances Registration (October 1, 2019)

Importer of Controlled Substances Registration (October 1, 2019)

CreaGen Inc. (October 1, 2019)

Siemens Healthcare Diagnostics, Inc. (October 1, 2019)

Noramco Inc. (October 1, 2019)


September

Final Rule: New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222) (September 30, 2019)

Importer of Controlled Substances Registration (September 20, 2019)

National Center for Natural Products Research NIDA MPROJECT (September 20, 2019)

Peter J. Waidzunas, D.D.S.; Decision and Order (September 20, 2019)

John Yolman Salinas, M.D.; Decision and Order (September 20, 2019)

Globyz Pharma, LLC (September 20, 2019)

Fisher Clinical Services, Inc. (September 20, 2019)

Fisher Clinical Services, Inc. (September 20, 2019)

Galephar Pharmaceutical Research Inc. (September 20, 2019)

Proposed Rule: Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance (September 17, 2019)

Proposed Rule: Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals (September 13, 2019)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (September 12, 2019)

Jeffrey Stein, M.D.; Decision and Order (September 6, 2019)


August

Importer of Controlled Substances Registration (August 29, 2019)

Cerilliant Corporation (August 29, 2019)

Nanosyn, Inc. (August 27, 2019)

Bulk Manufacturers of Marihuana (August 27, 2019)

Akorn, Inc. (August 27, 2019)

Cerilliant Corporation (August 27, 2019)

Cayman Chemical Company (August 26, 2019)

Cambrex High Point, Inc. (August 26, 2019)

AMRI Renesselaer, Inc. (August 26, 2019)

AMPAC Fine Chemicals Virginia, LLC (August 26, 2019)

Clinical Supplies Management Holdings, Inc. (August 26, 2019)

Cambrex High Point, Inc. (August 26, 2019)

Proposed Rule: Removal of 6β-naltrexol From Control (August 21, 2019)

Final Rule: Listing of Noroxymorphone in the Code of Federal Regulations and Assignment of a Controlled Substances Code Number (August 16, 2019)

Peter John Ulbrich, M.D.; Decision and Order (August 16, 2019)

Brent E. Silvers, M.D.; Decision and Order (August 16, 2019)

Alcami Wisconsin Corporation (August 8, 2019)

Parth S. Bharill; Decision and Order (August 8, 2019)

Anthony Schapera, M.D.; Decision and Order (August 8, 2019)


July

Importer of Controlled Substances Registration (July 30, 2019)

Chemtos, LLC (July 30, 2019)

Research Triangle Institute (July 30, 2019)

AMPAC Fine Chemicals LLC (July 30, 2019)

Alcami Carolinas Corporation (July 30, 2019)

Research Triangle Institute (July 30, 2019)

Cambrex Charles City (July 30, 2019)

Catalent Pharma Solutions, LLC (July 30, 2019)

Xcelience (July 30, 2019)

Nostrum Laboratories, Inc. (July 30, 2019)

Southern Ohio Correctional Facility (July 30, 2019)

Chattem Chemicals (July 30, 2019)

IsoSciences, LLC (July 24, 2019)

Cardinal Health (July 24, 2019)

Restek Corporation (July 24, 2019)

AMRI Rensselaer, Inc. (July 24, 2019)

Temporary Scheduling Order: Temporary Placement of N-Ethylhexedrone, α-PHP, 4–MEAP, MPHP, PV8, and 4-Chloro-α-PVP in Schedule I (July 18, 2019)

Importer of Controlled Substances Registration (July 2, 2019)

Absolute Standards, Inc. (July 2, 2019)

Pisgah Laboratories, Inc. (July 2, 2019)

Sigma Aldrich Co., LLC (July 2, 2019)

Bellwyck Clinical Services (July 2, 2019)

Lipomed (July 2, 2019)


June

VHG Labs DBA LGC Standards (June 24, 2019)

Final Rule: Placement of Thiafentanil in Schedule II (June 18, 2019)

Importer of Controlled Substances Registration (June 17, 2019)

Interim Final Rule: Placement of Brexanolone in Schedule IV (June 17, 2019)

Interim Final Rule: Placement of Solriamfetol in Schedule IV (June 17, 2019)

Bulk Manufacturer of Controlled Substances Registration (June 13, 2019)

Sigma Aldrich Research (June 13, 2019)

Eli-Elsohly Laboratories (June 13, 2019)

Elizabeth C. Korcz, M.D.; Decision and Order (June 13, 2019)

Bulk Manufacturer of Controlled Substances Registration (June 6, 2019)

American Radiolabeled Chem (June 6, 2019)

SpecGx LLC (June 6, 2019)

Shertech Laboratories, LLC (June 6, 2019)


May

Importer of Controlled Substances Registration (May 22, 2019)

United States Pharmacopeial Convention (May 22, 2019)

30-Day Notice: Report of Mail Order Transactions (May 21, 2019)

Importer of Controlled Substances Registration (May 15, 2019)

Bulk Manufacturer of Controlled Substances Registration (May 15, 2019)

AMPAC Fine Chemicals Virginia, LLC (May 15, 2019)

Raquel Skidmore, M.D.; Decision and Order (May 15, 2019)

Fred J. Powell, M.D.; Decision and Order (May 15, 2019)

Rhodes Technologies (May 15, 2019)

Wildlife Laboratories, Inc. (May 15, 2019)

AndersonBrecon Inc. DBA PCI of Illinois (May 15, 2019)

S & B Pharma, Inc. (May 15, 2019)

AndersonBrecon, Inc. (May 15, 2019)

Final Rule: Placement of Furanyl Fentanyl, 4-Fluoroisobutyryl Fentanyl, Acryl Fentanyl, Tetrahydrofuranyl Fentanyl, and Ocfentanil in Schedule I; Correction (May 8, 2019)

Final Rule: Placement of beta-Hydroxythiofentanyl in Schedule I (May 8, 2019)

Notice of Intent: Temporary Placement of N-Ethylhexedrone, α-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-α-PVP in Schedule I (May 1, 2019)

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility